Taysha Gene Therapies (TSHA) Total Current Liabilities (2019 - 2026)

Taysha Gene Therapies (TSHA) has 8 years of Total Current Liabilities data on file, last reported at $20.1 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities fell 10.9% year-over-year to $20.1 million; the trailing twelve-month figure through Mar 2026 stood at $20.1 million (down 10.9% YoY), and the FY2025 full-year result was $26.6 million, up 1.24% from the prior year.
• Total Current Liabilities declined to $20.1 million in Q1 2026, from $26.6 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $180.5 million in Q3 2023 to a low of $20.1 million in Q1 2026.
• A 5-year average of $44.8 million and a median of $34.2 million in 2024 frame the typical range for Total Current Liabilities.
• Across the five-year window, Total Current Liabilities surged 444.53% in 2023 and sank 83.74% in 2024, its largest moves.
• Tracing TSHA's Total Current Liabilities over 5 years: stood at $62.8 million in 2022, then plunged by 41.46% to $36.8 million in 2023, then slipped by 28.65% to $26.2 million in 2024, then increased by 1.24% to $26.6 million in 2025, then dropped by 24.31% to $20.1 million in 2026.
• Business Quant data shows TSHA's Total Current Liabilities at $20.1 million in Q1 2026, $26.6 million in Q4 2025, and $28.6 million in Q3 2025.